Literature DB >> 8297538

Cellular mechanisms of atherogenesis.

P E DiCorleto1.   

Abstract

The study of vascular cell function and the interactions of endothelial cells (EC), smooth muscle cells (SMC), and monocyte-derived macrophages has expanded greatly during the past 20 years, and the resultant information has reformed our views on the genesis of atherosclerotic plaque. The concept of an activated or injured endothelium that exhibits properties distinct from healthy adult endothelium is now well accepted. Activated EC may exhibit proatherogenic behavior, including increased leukocyte adhesivity, procoagulant activity, and SMC mitogen production. Thrombin, a coagulation-system protease, may serve as a physiologic activator of EC. Thrombin at sites of vascular injury may stimulate diverse functions, including increased expression of monocyte adhesion proteins and platelet-derived growth factor (PDGF). The monocyte-derived macrophage has been implicated as a participant in several aspects of atherosclerotic plaque development. The attachment of monocytes to EC is the initial event in the interaction of these cells with the vessel wall. Distinctly focal adhesion of monocytes to EC of large vessels is one of the earliest documented events in experimentally induced atherosclerosis and, thus, regulation of this process may be critical to the development of the disease. Intimal proliferation of SMC is another hallmark of the atherosclerotic lesion. Platelet-derived growth factor is both a chemoattractant and mitogen for SMC. Therefore, if EC secrete PDGF abluminally, both the migration of SMC into the intima and subsequent proliferation will be stimulated. Immunocytochemistry and insitu hybridization have verified that vascular EC express PDGF mRNA and protein in vivo under certain conditions.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8297538

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  8 in total

Review 1.  Endothelial function. General considerations.

Authors:  H Haller
Journal:  Drugs       Date:  1997       Impact factor: 9.546

2.  Lower-extremity functional electrical stimulation decreases platelet aggregation and blood coagulation in persons with chronic spinal cord injury: a pilot study.

Authors:  Nighat N Kahn; Susan P Feldman; William A Bauman
Journal:  J Spinal Cord Med       Date:  2010       Impact factor: 1.985

Review 3.  Endothelium, inflammation, and diabetes.

Authors:  Paresh Dandona
Journal:  Curr Diab Rep       Date:  2002-08       Impact factor: 4.810

4.  Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury.

Authors:  N N Kahn; W A Bauman; A K Sinha
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

Review 5.  Ulster says 'NO'; explosion, resistance and tolerance. Nitric oxide and the actions of organic nitrates.

Authors:  G D Johnston
Journal:  Ulster Med J       Date:  1998-11

Review 6.  The impact of reactive oxygen species in the development of cardiometabolic disorders: a review.

Authors:  Roland Akhigbe; Ayodeji Ajayi
Journal:  Lipids Health Dis       Date:  2021-02-27       Impact factor: 3.876

7.  Gene Expression Profiling of Apoptotic Proteins in Circulating Peripheral Blood Mononuclear Cells in Type II Diabetes Mellitus and Modulation by Metformin.

Authors:  Mohammed Al Dubayee; Awad Alshahrani; Dana Aljada; Mahmoud Zahra; Ahmed Alotaibi; Ibrahim Ababtain; Malik Alnaim; Ali Alahmari; Abdullah Aljarallah; Muhammad Affan Elahi; Hana M A Fakhoury
Journal:  Diabetes Metab Syndr Obes       Date:  2021-03-15       Impact factor: 3.168

8.  Formation of composite endothelial cell-mesenchymal stem cell islets: a novel approach to promote islet revascularization.

Authors:  Ulrika Johansson; Ida Rasmusson; Simone P Niclou; Naomi Forslund; Linda Gustavsson; Bo Nilsson; Olle Korsgren; Peetra U Magnusson
Journal:  Diabetes       Date:  2008-06-02       Impact factor: 9.461

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.